中等度から重度の慢性尋常性乾癬の成人被験者におけるビメキズマブの有効性と安全性をプラセボおよび実薬対照と比較評価する試験

基本情報

NCT ID: NCT03370133
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 567
治験依頼者名: UCB Pharma

概要

This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

対象疾患

Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisPsoriatic Arthritis

介入

Bimekizumab(DRUG)

Ustekinumab(DRUG)

Placebo(OTHER)

依頼者（Sponsor）

ユーシービージャパン(INDUSTRY)

実施施設 (30)

Ps0009 609

Kobe, Japan

Ps0009 607

Chiyoda City, Japan

Ps0009 616

Tsu, Japan

Ps0009 621

Nagoya, Japan

Ps0009 601

Fukuoka, Japan

Ps0009 605

Bunkyō City, Japan

Ps0009 626

Shinjuku-Ku, Japan

Ps0009 618

Shinjuku-Ku, Japan

Ps0009 612

Shinjuku-Ku, Japan

Ps0009 602

Shinagawa-Ku, Japan

Ps0009 620

Hamamatsu, Japan

Ps0009 600

Kurume, Japan

Ps0009 627

Itabashi-Ku, Japan

Ps0009 614

Osaka, Japan

Ps0009 619

Gifu, Japan

Ps0009 628

Shinjuku-Ku, Japan

Ps0009 615

Sumida City, Japan

Ps0009 610

Chūōku, Japan

Ps0009 603

Sapporo, Japan

Ps0009 606

Takaoka, Japan

Ps0009 604

Minatoku, Japan

Ps0009 611

Osaka, Japan

Ps0009 608

Itabashi-Ku, Japan

Ps0009 629

Asahikawa, Japan

Ps0009 622

Matsumoto, Japan

Ps0009 617

Sendai, Japan

Ps0009 625

Nankoku, Japan

Ps0009 624

Obihiro, Japan

Ps0009 613

Shimotsuke, Japan

Ps0009 623

Morioka, Japan